Linagliptin 1a Pharma

Linagliptin, the active ingredient in Linagliptin 1a Pharma, is a Dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adults, helping to improve glycaemic control when used with diet and exercise. GNH USA supplies Linagliptin 1a Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linagliptin is a DPP‑4 inhibitor used in the treatment of type 2 diabetes mellitus, acting on the incretin pathway to regulate blood glucose. - Type 2 diabetes mellitus (monotherapy): lowers fasting and post‑prandial glucose levels. - Type 2 diabetes mellitus (combined with metformin): enhances overall glycaemic control. - Type 2 diabetes mellitus (adjunct to lifestyle modification): supports blood‑sugar management alongside diet and exercise.

Common Side Effects: - Nasopharyngitis: mild inflammation of the nose and throat. - Headache: transient mild to moderate pain. - Gastrointestinal upset: includes nausea, abdominal discomfort, or diarrhoea. - Dizziness: occasional light‑headed sensation. - Back pain: intermittent musculoskeletal discomfort. - Arthralgia: joint pain without swelling.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain with elevated enzymes. - Severe hypersensitivity: rash, angioedema, or anaphylaxis. - Hepatic injury: marked elevation of liver enzymes. - Bullous skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Severe hypoglycaemia: when combined with insulin or sulfonylureas. - Angioedema: swelling of face, lips, or airway.

Linagliptin should be prescribed after evaluating patient‑specific factors and monitoring for adverse events. - Renal impairment: assess kidney function; dose adjustment may be required. - Hepatic disease: monitor liver enzymes regularly. - Elderly patients: watch for hypoglycaemia when used with insulin or sulfonylureas. - Pregnancy and lactation: use only if potential benefit justifies potential risk. - Drug interactions: review concomitant medications for additive effects. - Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Linagliptin may interact with several drug classes, requiring clinical vigilance. Major Interactions (Avoid): - Insulin: increased risk of hypoglycaemia. - Sulfonylureas: additive hypoglycaemic effect. - Strong CYP3A4 inhibitors: may raise linagliptin plasma levels. Moderate Interactions (Monitor Closely): - ACE inhibitors: monitor renal function and electrolytes. - Diuretics: watch for changes in fluid balance. - Warfarin: periodic INR checks recommended.